Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? (Q43795697)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published in November 2001

Language	Label	Description	Also known as
English	Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?	scientific article published in November 2001

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

positron emission tomography

1 reference

based on heuristic

inferred from title

Peter Vandenberghe

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Sigrid G. Stroobants

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

K Spaepen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

P Dupont

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J Thomas

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J Balzarini

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

C De Wolf-Peeters

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

L Mortelmans

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

G Verhoef

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

115

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

272-278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11703321%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Incidence of second cancers in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Maximum likelihood reconstruction for emission tomography

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03169.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43795697&oldid=2143375918"